Drug Utilization Research / Health policy and governance

(B-070) Applicability of Real-World Data for Healthcare Decision-Making: A Review and Comparison of Guidelines

(B-067) Assessing the Impact of COVID-19 Lockdown on Methadone and Buprenorphine Prescriptions in England: An Interrupted Time Series Analysis

(B-082) Assessing the Impact of Volume-Based Procurement on Antidepressant Accessibility and Inequality: A Four-City Cohort Study Using Drug Sales Data

(B-079) Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs)

(B-057) DARWIN EU® - Trends of use of Glucagon-like peptide-1 Receptor Agonists in real-world data from five European countries

(B-058) DARWIN-EU ®- Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics

(B-069) Differences in Characteristics and Clinical Benefits of Pivotal Trials Supporting Regulatory Approval of “Breakthrough” Drugs in the US and China

(B-085) Estimating Travel Time and Spatial Access to Insulin in China Before and After National Volume-Based Procurement: A Geospatial Analysis

(B-080) Evaluation of Real-World Evidence in Regulatory and HTA Submissions

(B-077) Evolving Landscape of Post-Marketing Surveillance (PMS) Studies in Japan Utilising Secondary Real-World Data (RWD)

(B-074) From Catalogue to Clarity: Characterizing Chinese Data Sources for Post-Authorization Real-World Studies

(B-068) Impact of andexanet alfa introduction on mortality and thromboembolic events, before and after Tuscan guidelines, in patients treated with rivaroxaban or apixaban with major bleeding

(B-081) Impact of Hospital Market Concentration on Spatial Accessibility and Inequality of Antidepressants Before and After Volume-Based Procurement in China

(B-062) Impact of Medicaid Mandatory Medication-Assisted Treatment (MAT) Benefit on Opioid Use Disorder Treatment Utilization, 2018-2022

(B-064) Impact of supply chain disruptions and drug shortages on drug utilization: a scoping review

(B-066) Impact of the antibiotics management policy and the COVID-19 pandemic on antimicrobial usage in Japan: A nationwide serial cross-sectional study

(B-087) Missed Opportunities for Patient Recruitment in Clinical Trials for Rare Cancers

(B-086) Nervous System Medication Dispensing Patterns Following Teleconsultations in France from January 2021 to June 2023: A Repeated Cross-sectional Study Using the National Health Data System

(B-063) Off-label Use of Glucagon-like Peptide 1 Agonists (GLP-1): Evidence from Medicare Part D

(B-060) Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces

(B-089) Optimizing Healthcare Outcomes in Ambulatory Patients through Clinical Pharmacist-Led Services

(B-075) Persistence of Medical Marijuana Use among Certified Patients in the State of Florida

(B-073) Pharmacists' Perspectives on Antibiotic Shortages: Implications for Clinical Practice in Australia

(B-072) Prescribing pattern of medicines at orthopedics outpatient department of a tertiary care hospital

(B-065) Regional Impact of the COVID-19 Pandemic on Polypharmacy Reduction Policies in Japan: A Nationwide Serial Cross-Sectional Study

(B-084) Residential Proximity to the Coast and Antidepressant Medication Use: Moderating Effects of Seasonal Variation

(B-078) Stakeholder Analysis of Responses to the FDA’s Discussion Paper on Artificial Intelligence and Machine Learning in Drug and Biological Product Development

(B-088) The evolving landscape of clinical trials in Peru

(B-059) The impact of drug shortages in the use of medicines across 52 real-world data sources in 19 countries in Europe and North America

(B-076) The Inflation Reduction Act Lowers Out-of-Pocket Costs for Orally-Administered Blood Cancer Therapies

(B-071) Uncertainty in Pre-approval and Post-approval Clinical Evidence of Drugs Granted Conditional Approval in China

(B-083) Use of Belatacept and Tacrolimus Among Kidney Transplant Recipients From 2011-2020: Comparing United States Renal Data System (USRDS) and Scientific Registry of Transplant Recipients (SRTR)

(B-061) Utilization of Nationwide Claims Data Mapped to OMOP Common Data Model to Enhance Post-Marketing Drug Safety Studies